Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa proof-of-concept study of ND-003 in idiopathic pulmonary fibrosis
CTR20262927Phase 2Active
- Sponsor
- Xinyue Biotech
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ND-003 in idiopathic pulmonary fibrosis (IPF), sponsored by Xinyue Biotech. Started Aug 2026; status: active.
02
Drugs
ND-003
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20262927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262927.